News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 18, 2020, 08:17 ET Orexo and Lyfebulb Partner During Unprecedented Times to Help Those Struggling With Alcohol and Opioid Use Disorders

Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a...

May 15, 2020, 04:54 ET Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI

Orexo's partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI...

May 11, 2020, 02:24 ET Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression

Orexo AB (publ.) today announces it has acquired the exclusive US rights to GAIA AG's (GAIA) deprexis®, a digital therapy to help patients manage...

Apr 28, 2020, 02:46 ET Orexo Presents the Interim Report for Q1 2020

Q1 2020 highlights Total net revenues of SEK 175.0 m (174.3), up 0.4 percent EBITDA of SEK 39.1 m (12.0), up 225.8 percent Net earnings of SEK 82.6 m ...

Apr 16, 2020, 13:56 ET James Noble Appointed as Chairman of the Board

Orexo AB (publ.) today announces the appointment of James Noble as Chairman of the Board. The resolution was taken today at the annual general...

Apr 16, 2020, 13:07 ET Notice of Extraordinary General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the extraordinary general meeting, to be held...

Apr 16, 2020, 12:25 ET Report from Orexo's Annual General Meeting, 16 April 2020

Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 16 April 2020 resolved, in accordance with the...

Apr 09, 2020, 11:39 ET The Board of Directors of Orexo Withdraws Proposal on Incentive Program

The board of directors of Orexo AB (publ) has resolved to withdraw the previously communicated proposals to the annual general meeting 2020...

Apr 06, 2020, 02:12 ET Orexo Ends Share Buy-back Program

Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 shares,...

Mar 26, 2020, 09:15 ET Orexo Publishes the Annual Report for 2019

Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be downloaded on the company's ...

Mar 25, 2020, 16:52 ET Orexo Has Repurchased 14 Percent of Own Corporate Bonds

Orexo AB (publ.) has repurchased 14 percent of its outstanding unsecured corporate bonds with a nominal value of SEK 40,500,000 through several...

Mar 17, 2020, 03:34 ET Orexo Presents Sales Potential of the Pharmaceutical Pipeline and Digital Therapies During the Capital Markets Day

Orexo AB (publ.), today hosts a Capital Market Day in Stockholm, Sweden. On the day the company will present an overview of the company's growth...

Mar 16, 2020, 16:05 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...

Mar 12, 2020, 13:08 ET Invitation to Attend Orexo's Capital Markets Day via Teleconference

As previously communicated, Orexo invites investors, analysts and the media to participate in the company's Capital Markets Day in Stockholm, Sweden, ...

Mar 06, 2020, 02:26 ET Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US

Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable...

Feb 19, 2020, 03:05 ET Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17

Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden, on...

Feb 17, 2020, 02:23 ET Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares

The board of Orexo AB (publ.) has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019, to initiate a...

Jan 30, 2020, 03:39 ET Q4 Incl. Full Year Report 2019

Q4 2019 highlights Total net revenues of SEK 238.1 million (227.1), up 4.8 percent Zubsolv® US net revenues of SEK 190.5 million (166.7), up 14.3...

Jan 29, 2020, 02:16 ET Promising Results From Human PK Study Assessing Novel Ketorolac Formulations for Treatment of Pain

Orexo AB (publ.) today announces promising results from its OX338 pharmacokinetic study, evaluating novel formulations of ketorolac, a non-addictive, ...

Dec 03, 2019, 09:15 ET Save the Date: Orexo to Host Capital Markets Day focusing on Digital Health, on March 17, 2020

Orexo AB (publ.), the fully integrated specialty pharmaceutical company with the aim of becoming a leader in the treatment of addiction, today...

Dec 02, 2019, 02:17 ET Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health

Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today...

Nov 27, 2019, 09:46 ET Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy

Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today...

Nov 08, 2019, 07:14 ET Orexo to Present at Jefferies 2019 Healthcare Conference

Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will...

Oct 24, 2019, 02:44 ET Orexo Interim Report Q3 2019

Strong financials paving the way for broadening the business UPPSALA, Sweden, Oct. 24, 2019 Q3 2019 highlights Total net revenues of SEK 231.2...

Oct 14, 2019, 12:01 ET Orexo´s Nomination Committee for the Annual General Meeting 2020

Prior to the Annual General Meeting (AGM) in 2020, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number ...